Research & Development
Baxter launches ready-to-use cardiovascular medicine norepinephrine in premix formulation
24 September 2021 -

Healthcare company Baxter International Inc (NYSE:BAX) announced on Thursday the commercial availability of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine) following approval from the US Food and Drug Administration (FDA).

Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).

According to Baxter, its formulation of norepinephrine is the first and only manufacturer-prepared ready-to-use formulation. It is available in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths.

Login
Username:

Password: